Standard dosage and usage guide for Rubicatin/Rubitigine

Lurbinectedin is a new type of anti-cancer drug that mainly inhibits the growth and spread of tumor cells by targeting RNA polymerase II in the transcription mechanism. In clinical use, the common recommended dose of this drug is 3.2 mg/m², which is administered by intravenous infusion and repeated every 21 days. The specific course of treatment is determined by the doctor based on the patient's tolerance and disease control. This dose setting is based on the results of multiple overseas key clinical studies and is currently the most widely recognized standard usage.

The administration time of rubitin is generally controlled within 60 minutes, and it is recommended that the infusion be carried out in an experienced oncology department to handle the adverse reactions promptly. Because it has a certain risk of bone marrow suppression, blood pictures, including neutrophil count, platelet levels and other indicators, should be monitored regularly before use to avoid the occurrence of serious infection or bleeding. In addition, liver function and renal function are also important indicators that need to be paid attention to before evaluating medication. For patients with significantly abnormal liver function or low creatinine clearance, doctors may adjust the dosage or extend the dosing interval as appropriate.

In actual use, attention should also be paid to drug interactions, especially to avoid simultaneous use of strongCYP3A4 inhibitors or inducers, because they may affect the metabolism of rubitidine, resulting in weakened efficacy or enhanced toxicity. It is worth noting that although rubitidine is still a new drug in China, its usage and dosage have been in line with international guidelines, and it has gradually occupied a more important treatment position in the field of solid tumors, especially small cell lung cancer (SCLC). Standardized usage not only helps to improve the efficacy, but also helps to reduce the incidence of side effects, which is a key prerequisite for achieving personalized and precise medication.

Reference materials:https://www.zepzelca.com/